We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2015;314(16):1669-1671. doi:10.1001/jama.2014.12047.
Text Size: A A A
Published online


Emerging data suggest that intravenous saline may contribute to acute kidney injury (AKI) among critically ill patients and that buffered crystalloid solutions may be associated with a decreased risk of AKI. In a cluster randomized trial that enrolled 2278 intensive care unit patients requiring crystalloid fluid therapy, Young and colleagues found no difference in AKI risk among patients randomly assigned to receive a buffered crystalloid compared with those assigned to receive saline. In an Editorial, Kellum and Shaw discuss unresolved questions regarding the toxicity of intravenous crystalloids in critically ill patients.

Noninvasive ventilation has been recommended to decrease mortality among immunocompromised patients with acute hypoxemic respiratory failure. In a multicenter randomized trial that enrolled 374 adult patients with immune system compromise and acute hypoxemic respiratory failure, Lemiale and colleagues found that compared with oxygen therapy alone, early noninvasive ventilation did not reduce 28-day mortality rates. In an Editorial, Patel and Kress discuss advances in noninvasive ventilation technology and implications for patient care.


A long-acting β-agonist (LABA) in combination with inhaled corticosteroids is recommended for patients with poor asthma control. However, concerns exist about the safety and efficacy of LABA therapy among black patients with asthma. Whether a long-acting anticholinergic can substitute for LABAs is unclear. Wechsler and colleagues investigated these treatment-related concerns in 1070 black adults with moderate or severe asthma. The authors found no difference in time to asthma exacerbation among patients randomly assigned to either a LABA or tiotropium—a long-acting anticholinergic—combined with inhaled corticosteroid.

Ma and colleagues analyzed 1969-2013 national vital statistics data to assess temporal trends in mortality in the United States. Among the findings was a decreasing trend in the age-standardized death rate for all causes combined, as well as for heart disease, cancer, stroke, unintentional injures, and diabetes. The mortality rate for chronic obstructive pulmonary disease increased from 1969 to 2013. In an Editorial, McGinnis discusses limitations of mortality trends to assess health status in the United States.


A 73-year-old woman with a history of pulmonary sarcoidosis had a widespread scaly rash that did not improve with topical triamcinolone. Her medications included amlodipine, hydroxychloroquine, and pantoprazole. Laboratory testing revealed an antinuclear antibody titer of 1:80, with no elevation of double-stranded DNA, Smith, or antihistone antibodies. Skin biopsy revealed an inflammatory pattern of vacuolar interface dermatitis. What would you do next?

In a JAMA Diagnostic Test Interpretation article, Tritos and Klibanski present a 47-year-old man with recent-onset fatigue, vision loss, and low libido. The patient denied headache, erectile dysfunction, or breast tenderness. Physical examination was significant for bitemporal visual field defects; the patient did not have acromegalic features, gynecomastia, or galactorrhea. Laboratory evaluation revealed low testosterone and thyrotropin levels and elevated serum prolactin. How would you interpret the test results?

This Medical Letter on Drugs and Therapeutics article provides information about 3 available oral opioid formulations having 1 or more properties that make their intentional nontherapeutic use more difficult or less rewarding. Results of trials comparing abuse-deterrent opioids with original formulations and postmarketing epidemiological study data are summarized.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.